Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock
FibroGen, Inc (NASDAQ:FGEN) Director Jorma Routti sold 12,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $47.25, for a total value of $567,000.00. Following the transaction, the director now directly owns 133,840 shares of the company’s stock, valued at $6,323,940. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
FibroGen, Inc (NASDAQ FGEN) traded down $2.65 on Monday, hitting $44.50. The stock had a trading volume of 451,259 shares, compared to its average volume of 618,471. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen, Inc has a 1-year low of $19.25 and a 1-year high of $60.15.
FGEN has been the subject of a number of research reports. Jefferies Group reaffirmed a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, September 12th. Mizuho reaffirmed a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research note on Thursday, September 14th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Citigroup raised their price objective on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.67.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.